|Description||Binimetinib is an oral, highly selective MEK inhibitor.|
|B0084-455720||300 mg||$499||In stock|
|Synonyms||MEK162; MEK-162; MEK 162; ARRY162; ARRY-162; ARRY 162; ARRY438162, Binimetinib; 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide|
|Current Developer||Array Biopharm./Novartis.|
Binimetinib is an oral, highly selective MEK inhibitor.
Cobimetinib (R-enantiomer) is a selective inhibitor of MEK. It is also known as mitogen activated protein kinase kinase (MAPKK) and is a key component of the RA...
cobimetinib, also known as GDC-0973 and XL-518, is an orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1)...
Cobimetinib, also known as GDC-0973 and XL-518, is a novel selective MEK inhibitor, and the IC50value against MEK1 is 4.2 nM, with potential antineoplastic acti...
PD 198306, an amino-benzamide compound, is an orally bioavailable and potent inhibitor of MAPK kinase 1/2 (MEK1/2; IC50 = 8 nM). It inhibits isolated enzyme at ...
Trametinib is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM and no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2.
PD 334581, an analog of PD 184352, is an inhibitor of MEK1 that is used in biological studies to evaluate halogen bonding as a novel interaction for rational dr...
PD98059 is a potent and selective inhibitor of MAP kinase kinase (also known as MAPK/ERK kinase or MEK kinase). It mediates its inhibitory properties by binding...